Hart Cohen, MD
Neurology · Los Angeles, CANPI 1295763696
Payments from drug & device makers
Across 275 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- UCB, Inc.$768
- Sanofi$634
- Biogen$416
- AbbVie$388
- Lundbeck LLC$305
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$1593%
- Food & beverage$5,20897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 95 | $1,517 |
| UCB, Inc. | 38 | $768 |
| Sanofi | 27 | $634 |
| Biogen | 21 | $416 |
| AbbVie(2 entities) | 18 | $388 |
| Lundbeck LLC | 11 | $305 |
| Neurocrine Biosciences, Inc. | 9 | $195 |
| EMD Serono, Inc. | 10 | $164 |
| Acorda Therapeutics, Inc | 7 | $159 |
| Acadia Pharmaceuticals Inc | 7 | $130 |
| Lilly USA, LLC | 4 | $96 |
| MDD US Operations, LLC | 3 | $80 |
| Pfizer | 2 | $53 |
| Amgen | 3 | $47 |
| Argenx US, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| AstraZeneca(2 entities) | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Grifols USA, LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| SK Life Science, Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,367 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 146 | $855,583 |
| Kesimpta PenOfatumumab | 53 | $544,729 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 15 | $534,083 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $216,269 |
| AubagioTeriflunomide | 12 | $110,351 |
| RytaryCarbidopa/Levodopa | 84 | $94,478 |
| AmpyraDalfampridine | 22 | $92,858 |
| FingolimodFingolimod Hcl | 15 | $56,392 |
| Glatiramer Acetate | 26 | $52,173 |
| NeuproRotigotine | 35 | $40,269 |
| OngentysOpicapone | 31 | $35,240 |
| Nurtec OdtRimegepant Sulfate | 23 | $35,003 |
| TrileptalOxcarbazepine | 14 | $31,994 |
| Emgality PenGalcanezumab-Gnlm | 35 | $26,830 |
| NamzaricMemantine Hcl/Donepezil Hcl | 29 | $26,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $18 | $855,583146 claims |
| Grifols USA, LLCGamunex-C | $26 | $216,26913 claims |
| SanofiAubagio | $634 | $110,35112 claims |
| Acorda Therapeutics, IncAmpyra | $159 | $92,85822 claims |
| PfizerNurtec Odt, Lyrica, Dilantin | $53 | $47,11751 claims |
| AbbVieNamzaric, Savella | $388 | $42,62353 claims |
| UCB, Inc.Neupro | $768 | $40,26935 claims |
| Neurocrine Biosciences, Inc.Ongentys | $195 | $35,24031 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $11 | $9,82818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.